Artal Group S.A. Agenus Inc Transaction History

Artal Group S.A.

$214 Million
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$1.45 - $2.95 $1.64 Million - $3.34 Million	1,131,235 Added 7.8%	15,631,235 $23.8 Million
Q4 2022 Feb 13, 2023	BUY	$2.02 - $3.25 $21.2 Million - $34.1 Million	10,500,000 Added 262.5%	14,500,000 $34.8 Million
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.14 $1.96 Million - $3.14 Million	1,000,000 Added 33.33%	4,000,000 $8.2 Million
Q2 2022 Aug 11, 2022	SELL	$1.3 - $2.64 $3.25 Million - $6.6 Million	-2,500,000 Reduced 45.45%	3,000,000 $5.82 Million
Q1 2022 May 12, 2022	SELL	$2.35 - $3.47 $2.35 Million - $3.47 Million	-1,000,000 Reduced 15.38%	5,500,000 $13.5 Million
Q4 2021 Feb 11, 2022	BUY	$2.92 - $5.74 $2.92 Million - $5.74 Million	1,000,000 Added 18.18%	6,500,000 $20.9 Million
Q3 2021 Nov 12, 2021	SELL	$4.98 - $6.63 $2.49 Million - $3.32 Million	-500,000 Reduced 8.33%	5,500,000 $28.9 Million
Q1 2021 May 14, 2021	SELL	$2.69 - $5.25 $2.42 Million - $4.73 Million	-900,000 Reduced 13.04%	6,000,000 $16.3 Million
Q3 2020 Nov 13, 2020	BUY	$2.98 - $5.2 $12.1 Million - $21.1 Million	4,050,000 Added 142.11%	6,900,000 $27.6 Million
Q2 2020 Aug 14, 2020	BUY	$2.29 - $4.24 $801,500 - $1.48 Million	350,000 Added 14.0%	2,850,000 $11.2 Million
Q2 2019 Aug 09, 2019	SELL	$2.53 - $3.04 $632,500 - $760,000	-250,000 Reduced 9.09%	2,500,000 $7.5 Million
Q1 2018 May 10, 2018	BUY	$3.51 - $6.04 $876,604 - $1.51 Million	249,745 Added 9.99%	2,750,000 $13 Million
Q4 2017 Feb 09, 2018	BUY	$3.26 - $4.78 $831 - $1,218	255 Added 0.01%	2,500,255 $8.15 Million
Q3 2017 Nov 08, 2017	BUY	$3.48 - $4.44 $8.7 Million - $11.1 Million	2,500,000	2,500,000 $11 Million

Others Institutions Holding AGEN

# of Institutions

Shares Held

2.07M

Call Options Held

Put Options Held

View Full List

About AGENUS INC

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

More about AGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account